GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aytu BioPharma Inc (NAS:AYTU) » Definitions » Accumulated Depreciation

AYTU (Aytu BioPharma) Accumulated Depreciation : $-1.87 Mil (As of Sep. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Aytu BioPharma Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Aytu BioPharma's quarterly accumulated depreciation declined from Mar. 2024 ($-2.87 Mil) to Jun. 2024 ($-2.13 Mil) but then stayed the same from Jun. 2024 ($-2.13 Mil) to Sep. 2024 ($-1.87 Mil).

Aytu BioPharma's annual accumulated depreciation increased from Jun. 2022 ($-2.42 Mil) to Jun. 2023 ($-3.68 Mil) but then stayed the same from Jun. 2023 ($-3.68 Mil) to Jun. 2024 ($-2.13 Mil).


Aytu BioPharma Accumulated Depreciation Historical Data

The historical data trend for Aytu BioPharma's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aytu BioPharma Accumulated Depreciation Chart

Aytu BioPharma Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.48 -1.01 -2.42 -3.68 -2.13

Aytu BioPharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.99 -3.08 -2.87 -2.13 -1.87

Aytu BioPharma Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.


Aytu BioPharma Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Aytu BioPharma's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.


Aytu BioPharma Business Description

Traded in Other Exchanges
Address
7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
Executives
Christopher Brooke officer: Chief Operating Officer C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112
Jarrett Disbrow officer: Chief Business Officer 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112
John Jr. Donofrio director C/O AYTU BIOSCIENCE, INC., 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112
Carl Dockery director P.O. BOX 2477, LAKELAND FL 33806-2477
Vivian H Liu director
Mark K Oki officer: Chief Financial Officer C/O ALEXZA PHARMACEUTICALS INC, 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Joshua R. Disbrow director, officer: Chief Executive Officer AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Abhinav Jain director C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112
Wilmot B. Harkey 10 percent owner C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Daniel Mack 10 percent owner C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Nantahala Capital Management, Llc 10 percent owner 130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Greg Pyszczymuka officer: Chief Commerical Officer C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112
Richard I Eisenstadt officer: Chief Financial Officer 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Gerald W. Mclaughlin director 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Beth Hecht director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050